EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making

Rachel Hellemans, Liset H M Pengel iD, Sylvain Choquet, Umberto Maggiore iD, for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project

Transplant International · 2021-10 · 34 (10) · 1789-1800

DOI: 10.1111/tri.13952 ↗

At a glance

Übersichtsarbeit in Transplant International, published online on 2021-09-27. Written by Rachel Hellemans and 4 co-authors. Institution: Department of Nephrology, Antwerp University Hospital, Edegem, Belgium. Major MEDLINE topics: Kidney Transplantation, Skin Neoplasms. Cited 24 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Kidney transplant recipients (KTRs) have increased incidence of de novo cancers. After having undergone treatment for cancer with curative intent, reducing the overall immunosuppressive load and/or switching to an alternative drug regimen may potentially be of great benefit to avoid cancer recurrence, but should be balanced against the risks of rejection and/or severe adverse events. The TLJ (Transplant Learning Journey) project is an initiative from the European Society for Organ Transplantation (ESOT). This article reports a systematic literature search undertaken by TLJ Workstream 3 to answer the questions: (1) Should we decrease the overall anti-rejection therapy in potentially cured post-kidney transplant cancer (excluding non-melanoma skin cancer)? (2) Should we switch to mammalian target of rapamycin inhibitors (mTORi) in potentially cured post-kidney transplant cancer (excluding non-melanoma skin cancer)? The literature search revealed insufficient solid data on which to base recommendations, so this review additionally presents an extensive overview of the indirect evidence on the benefits versus risks of alterations in immunosuppressive medication. We hope this summary will help transplant physicians advise KTRs on how best to continue with anti-rejection therapy after receiving cancer treatment with curative intent, and aid shared decision-making, ensuring that patient preferences are taken into account.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationSkin NeoplasmsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsNeoplasm Recurrence, Local

Author keywords

cancerimmunosuppressionkidney transplantationmTORirejection

Substances

Immunosuppressive Agents

Authors and institutions

  • Department of Nephrology, Antwerp University Hospital, Edegem, Belgium.
  • Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Edegem, Belgium.
  • Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Service d'Hématologie, Hôpital Pitié Salpêtrière, Paris, France.
  • Nephrology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.

ORCID profiles: Liset H M Pengel, Umberto Maggiore

Cite

APA

Hellemans, R., Pengel, L. H. M., Choquet, S., Maggiore, U., & for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project (2021). Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making. Transplant International, 34(10), 1789-1800. https://doi.org/10.1111/tri.13952

Vancouver

Hellemans R, Pengel LHM, Choquet S, Maggiore U, for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project. Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making. Transplant International. 2021;34(10):1789-1800. doi:10.1111/tri.13952

BibTeX
@article{Hellemans2021,
  author = {Hellemans, Rachel and Pengel, Liset H M and Choquet, Sylvain and Maggiore, Umberto and for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project, for ESOT Workstream 3 of the TLJ (Transplant Learning Journey) project},
  title = {Managing immunosuppressive therapy in potentially cured post‐kidney transplant cancer (excluding non‐melanoma skin cancer): an overview of the available evidence and guidance for shared decision‐making},
  journal = {Transplant International},
  year = {2021},
  volume = {34},
  number = {10},
  pages = {1789--1800},
  doi = {10.1111/tri.13952}
}
Start for free →